J&J issues new heart risk warnings to Haldol

09/17/2007 | Yahoo!

Johnson & Johnson has added new labeling to its schizophrenia drug Haldol noting potential risks of death and dangerous cardiovascular events, the FDA said Monday. J&J issued the warnings following reports of sudden death and QT prolongation in some patients, most of whom either took the drug intravenously or in higher doses, the FDA announced on its Web site.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR